Abstract: A cloud based pulse oximetry system and method is provided that incorporates both a software and hardware component. The hardware component includes a limited use pulse oximetry probe having an energy source and data transmitting capabilities. The probe houses a light source and a light detector that compare and calculate the differences in the oxygen-rich versus oxygen-poor hemoglobin in the body part to which, it is attached. Data from the probe is collected, analyzed, and communicated using a cloud based computing system. The system may be used for collecting and analyzing pulse oximetry data for any medical need such as diagnosis of obstructive sleep apnea.

Abstract: The technology concerns methods and compositions for diagnosing obstructive sleep apnea, a common condition observed in children. In certain embodiments, there are methods and compositions relating to the use of novel biomarkers to diagnose obstructive sleep apnea.

Abstract: One aspect of the present invention is to assess the performance of automated analysis of blood oxygen saturation (SpO2) recordings as a screening tool for OSAHS. As an initial step, statistical, spectral and nonlinear features are estimated to compose an initial feature set. Then, a fast correlation-based filter (FCBF) is next applied to search for the optimum subset. Finally, the discrimination power (OSAHS negative vs. OSAHS positive) of three pattern recognition algorithms is assessed: linear discriminant analysis (LDA), quadratic discriminant analysis (QDA) and logistic regression (LR). According to another aspect of the invention, oximetry is used to determine the OSAHS severity in children. For testing the severity of OSAHS, first spectral analysis is conducted to define and characterize a frequency band of interest in SpO2.

Abstract: It was determined that plasma-derived exosomes from either obese (OB) or obstructive sleep apnea (OSA) children with evidence of endothelial dysfunction (ED). Such ED exosomes lead to up-regulation of adhesion molecules in endothelial cells. Exosomal miRNA cargo differences underlie the mechanisms accounting for the presence of ED. Specifically, expression of miRNA-630 is reduced in circulating exosomes of either obese or OSA children with ED, and normalizes in OSA children with ED after treatment along with restoration of endothelial function. These findings elucidate a novel role of exosomal miRNA-630 as a putative key mediator of vascular function and a biomarker of cardiovascular disease (CVD) risk in children.

Abstract: An in vitro method predicts the response to continuous positive airway pressure (CPAP) in a subject in need thereof. The method includes determining in an isolated sample of the subject the level of expression of a cardiovascular system functionally related microRNA differentially expressed in patients with cardiovascular disease. The microRNA is selected from the group: miR.100.5p, miR.378a.3p, miR.486.5p, and combinations thereof.

Abstract: The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.

Abstract: The technology concerns methods and compositions for diagnosing obstructive sleep apnea, a common condition observed in children. In certain embodiments, there are methods and compositions relating to the use of novel biomarkers to diagnose obstructive sleep apnea.

Abstract: The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.

Abstract: The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.

Abstract: The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.

Abstract: The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethylnitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOs to increase VE in freely behaving, conscious rats using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).

Abstract: A method of treating snoring and/or sleep apnea comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist.

Abstract: The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOs to increase VE in freely behaving, conscious rats using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).

Abstract: The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitro-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOg to increase VE in freely behaving, conscious rates using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).

Abstract: A method of treating snoring and/or sleep apnea comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist.

Abstract: A method for diagnosing obstructive sleep apnea in a patient comprises identifying at least one protein biomarker for obstructive sleep apnea; obtaining a sample from the patient; and testing the sample for presence of the at least one protein biomarker. The protein biomarkers may include alpha-1 B-glycoprotein; kallikrein, laminin, aldosterone-binding protein and/or urocortin-2 precursor. The presence of the protein biomarkers may be detected using antibodies. These antibodies may be provided in an array for detecting the presence of the at least one protein biomarker or a pattern of protein biomarkers.

Abstract: The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitro-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOg to increase VE in freely behaving, conscious rates using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).